SO YOU DRIVE to the local park for your morning walk, drive and take a Metro to your office, where you grab the lift to the third floor, and then you repeat the commute in the evening. If you have to queue up for an autorickshaw, you crib about last-mile connectivity to your doorstep, instead of walking that mile.
That’s rising urbanisation and sedentary lifestyles for you. The bane of modern India. But they are a boon for pharmaceutical companies such as Eli Lilly & Co, whose 146-year history has been powered by a list of firsts: the first treatment for pernicious anaemia, the first mass-produced antibiotic, the mass-produced Salk polio vaccine, human insulin, and pills for clinical depression and schizophrenia, among others.
Lilly is now betting that its drugs for obesity and diabetes will power its revenues into a higher trajectory. Especially as obesity and diabetes are like the proverbial chicken and egg situation: which came first? Lilly’s portfolio also has your heart covered (obesity and diabetes can get your heart).
RESPONDING TO THE DUAL CRISIS
US-based Lilly is no stranger to India. In 1993, it set up a unit to bring its treatments for diabetes, a range of cancers, osteoporosis, rheumatoid arthritis, men’s health, and growth hormone deficiency.
Now, it aims to bring to India its hugely successful drug Mounjaro that is used to treat Type 2 diabetes and as an anti-obesity drug for adults. In the US, Lilly has launched two different brands: Zepbound for obesity; and Mounjaro for Type 2 diabetes. In both, the active ingredient is tirzepatide. Mounjaro’s revenue exceeded $5 billion in 2023, its first full year on the market.
According to the FDA, approximately 70% of American adults are obese or overweight, and many of those overweight have a weight-related condition.
This story is from the March 31, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the March 31, 2024 edition of Business Today India.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Haute Couture in the Kitchen
FASHION BRANDS ARE ENTERING THE RESTAURANT SPACE, AS FOOD SEEMS TO HAVE BECOME THE ULTIMATE FASHION STATEMENT
It's Personal
Mixing work and personal tasks on work machines may be a done thing for many, but it makes sense to have a dedicated device for your personal needs. Here are two such devices
INTO THE BLUE
For WTiCabs Founder and CEO Ashok Vashist, scuba diving is not just an adventure sport. It is a pathway to connect with the ocean
"Challenges are opportunities"
AMIT JAIN CO-FOUNDER & CEO CARDEKHO GROUP CarDekho Group is a digital automotive solutions provider
THE WAIT FOR HIGHER PENSION
ALMOST 18 MONTHS AFTER THE SUPREME COURT RULING, SUBSCRIBERS WHO OPTED FOR A HIGHER PENSION UNDER THE EMPLOYEES' PENSION SCHEME CONTINUE TO WAIT AS THE EPFO, FACING A STAFF CRUNCH, TRIES TO FIGURE OUT THE MATH
"It's possible to have a 25% growth out of India from now on"
Rail Europe Executive Chairman & CEO Björn Bender talks about the India market, the shift to digital, and the way ahead
Evolving Strategies
Companies need to adapt to changing times for a strong workforce
PERKS PRESSURE
IT'S NOT JUST ABOUT THE MONEY ANYMORE FOR EMPLOYEES. FROM FOUR-DAY WORK WEEKS, TO SKILLING ON THE JOB AND MENTAL WELL-BEING EXERCISES, COMPANIES ARE OFFERING A HOST OF BENEFITS TO RETAIN TOP TALENT. IS THIS ENOUGH?
FOSTERING PLURALISM
Axis Bank, with its initiatives and policies, is striving to make a holistic difference to people's careers and hone their skills too
In Keeping With The Times
With a slew of initiatives for its employees, Abbott India is working hard to build a diverse and inclusive workforce
